HB

Introduction of Breast Imaging Legislation Will Benefit Thousands of Floridians

Retrieved on: 
Tuesday, January 9, 2024
Woman, Patient, Legislation, MRI, Food, HB, Google Images, Breast cancer, Disease, Breast MRI, Magnetic resonance imaging, Biopsy, Medical imaging

TALLAHASSEE, Fla., Jan. 9, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, commends Representative Marie Woodson (D-Pembroke Pines) and Senator Lori Berman (D-Boynton Beach) for working with Komen to eliminate financial barriers to earlier breast cancer detection by ensuring that everyone has equitable access to diagnostic and supplemental breast imaging.

Key Points: 
  • In 2023 alone, more than 22,670 individuals were diagnosed with breast cancer and approximately 3,170 died of the disease in Florida.
  • "Many Floridians in need of diagnostic and supplemental breast exams for the early detection of breast cancer are subjected to out-of-pocket costs that are simply unaffordable," said Senator Berman.
  • An estimated 12% of individuals are called back for additional imaging after an abnormal screening mammogram and require diagnostic imaging.
  • This diagnostic or supplemental imaging is often crucial for individuals previously diagnosed with breast cancer or those considered high-risk.

Introduction of Breast Imaging Legislation Will Benefit Thousands of Virginians

Retrieved on: 
Tuesday, January 9, 2024
Woman, Patient, Legislation, MRI, Health, HB, Google Images, Breast cancer, Map, Cancer, Prognosis, Disease, Breast MRI, Magnetic resonance imaging, Biopsy, Diagnosis, Medical imaging

RICHMOND, Va., Jan. 9, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, commends Delegate Shelly Simonds (D-Newport News) for working with Komen to eliminate financial barriers to earlier breast cancer detection by ensuring that everyone has equitable access to diagnostic and supplemental breast imaging.

Key Points: 
  • In Virginia, 7,810 women were diagnosed with breast cancer in 2023 and 1,150 died of the disease.
  • HB 230 , introduced by Delegate Simonds, eliminates the patient out-of-pocket costs for medically necessary diagnostic and supplemental breast imaging including MRIs, ultrasounds and diagnostic mammograms.
  • An estimated 12% of individuals are called back for additional imaging after an abnormal screening mammogram and require diagnostic imaging.
  • This diagnostic or supplemental imaging is often crucial for individuals previously diagnosed with breast cancer or those considered high-risk.

Financial Relief for Small Businesses in 2024: The Impact of House Bill 1004

Retrieved on: 
Thursday, December 28, 2023
HRA, Research, Growth, Health, Innovation, Culture, Small business, Regulation, Multimedia, HB, House

INDIANAPOLIS, Dec. 28, 2023 /PRNewswire/ -- House Bill 1004 is a legislative milestone that promises to positively reshape the landscape for small businesses and catalyze unprecedented growth.

Key Points: 
  • INDIANAPOLIS, Dec. 28, 2023 /PRNewswire/ -- House Bill 1004 is a legislative milestone that promises to positively reshape the landscape for small businesses and catalyze unprecedented growth.
  • This legislative initiative substantially impacts the small business landscape, and Remodel Health wants to ensure small business owners are well informed.
  • Some of the key benefits that the HB 1004 offers small business owners include the following:
    Tax Relief - HB 1004 brings forth comprehensive tax relief measures tailored to alleviate small businesses' burden.
  • HB 1004 simplifies and streamlines regulations, making it easier for small business owners to focus on what they do best—running and growing their businesses.

Study Finds Opto-Acoustic Imaging During Neoadjuvant Therapy Correlates to Pathologic Response

Retrieved on: 
Friday, December 8, 2023
Correlation, HB, Research, NAC, RCB, Neoadjuvant therapy, Feasibility study, University, Breast cancer, Cancer, Pathology, Patient, PCR, Medical imaging

Similarly, an increase in OA/US scan scores after cycle 1 may be an important indicator of poor response to chemotherapy, allowing for intervention earlier in the course of therapy.

Key Points: 
  • Similarly, an increase in OA/US scan scores after cycle 1 may be an important indicator of poor response to chemotherapy, allowing for intervention earlier in the course of therapy.
  • The poster Changes in Breast Cancer Opto-Acoustic Imaging Features During Neoadjuvant Therapy and Correlation with Pathologic Response: A Feasibility Study was presented on Friday, December 8, by Basak Dogan, MD, director of breast imaging research at the University of Texas Southwestern Medical Center, Department of Radiology, Harold C. Simmons Comprehensive Cancer Center.
  • The analysis highlights the role OA/US can play in predicting response to neoadjuvant therapy (NAC) by evaluating the OA/US imaging feature changes.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to developing and commercializing a new modality in cancer diagnosis: opto-acoustic imaging.

HB Capital and Social Capital Partners Establish Strategic Partnership to Advance Employee Ownership Initiatives

Retrieved on: 
Friday, December 22, 2023
Banking, Other Professional Services, Professional Services, Finance, Hand, Social capital, Partnership, HB, Bank

HB Capital is pleased to announce a strategic partnership with Social Capital Partners.

Key Points: 
  • HB Capital is pleased to announce a strategic partnership with Social Capital Partners.
  • The investment from Social Capital Partners underscores our shared vision of promoting sustainable business practices and empowering employees through ownership structures.
  • HB Capital and Social Capital Partners aim to create a blueprint for successful employee ownership initiatives within the private equity landscape, demonstrating that financial success and social impact can go hand in hand.
  • About HB Capital: HB Capital is a dynamic American investment firm committed to advancing employee ownership and creating sustainable opportunities for workers.

Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events

Retrieved on: 
Saturday, December 9, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Adolescence, Nasal congestion, Safety, Food, Hemolytic anemia, Sickle cell disease, ASH, Pain, Priapism, Acute myeloid leukemia, Patient, Disease, Acute chest syndrome, Hospital, Quality of life (healthcare), Fatigue, HB, Leukemia, Busulfan, Division, VOE, RAF Sullom Voe, Hemolysis, Myelodysplastic syndrome, Exposition, University, Diagnosis, Society, Quality of life, Biology, Blood transfusion, Bilirubin, Comorbidity, Pharmaceutical industry, Medical imaging, Anemia, Hematology

The majority of adverse events in treated patients were attributed to underlying sickle cell disease or conditioning with busulfan.

Key Points: 
  • The majority of adverse events in treated patients were attributed to underlying sickle cell disease or conditioning with busulfan.
  • Lovo-cel is the most deeply studied gene therapy in development for sickle cell disease, with the most patients treated and longest follow-up in the field.
  • As of February 13, 2023, 59 patients were treated across the entire clinical development program with follow-up beyond 8 years in the earliest treated patients.
  • In sickle cell disease, hemolysis happens too quickly due to the fragility of sickled red blood cells, resulting in hemolytic anemia.

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023

Retrieved on: 
Saturday, December 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bristol Myers Squibb, NYSE, European Commission, University, ASH, HB, Civil service commission, Patient, ASCO, BMY, Merck, ESA, MDS, Myelodysplastic syndrome, Anemia, MD Anderson Cancer Center, Society, RBC, ITT, Epoetin alfa, Pharmaceutical industry, Dietary supplement

These data are being presented in an oral presentation at the 2023 American Society of Hematology (ASH) Annual Meeting, from December 9-12.

Key Points: 
  • These data are being presented in an oral presentation at the 2023 American Society of Hematology (ASH) Annual Meeting, from December 9-12.
  • Reblozyl is being developed and commercialized through a global collaboration with Merck as of November 2021.
  • At the time of the primary analysis (March 31, 2023), 363 patients were randomized 1:1 to Reblozyl and epoetin alfa.
  • Erythroid response (HI-E) increase of at least 8 weeks was achieved by 74.2% (n=135) of Reblozyl patients vs. 53% (n=96) of epoetin alfa patients (p

Global Hemoglobin A1C (HbA1C) Testing Strategic Research Report 2023: Market to Reach $2.3 Billion by 2030 from $1.4 Billion in 2022 - Benefits of POC HbA1c Tests Over Lab Tests Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Friday, December 8, 2023
Medical Devices, Health, Glycated hemoglobin, POC, HPLC, American Diabetes Association, HB, Growth, COVID-19, Medical laboratory, Immunoassay, High-performance liquid chromatography, Diabetes, Pharmaceutical industry

The "Hemoglobin A1C (HbA1C) Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemoglobin A1C (HbA1C) Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The report discusses the impact of the COVID-19 pandemic on the utilization of Hemoglobin A1C (HbA1C) laboratory tests, highlighting a new challenge of underutilization.
  • It also provides insights into the competition within the HbA1C testing market, including the global key competitors' percentage market share in 2022.
  • The global market analysis and prospects for HbA1C testing are presented, with a focus on rapid growth in the world HbA1C testing market.

Insurers Combat Predatory Towing Practices in Florida

Retrieved on: 
Wednesday, December 6, 2023
Glass, Wagner de Campos Rosário, National Insurance, Representative, HB, Government, Insurance, National Insurance Crime Bureau, Florida House, Sunshine State, Frustration, Florida House of Representatives, Medicine, Policy, Lease

TALLAHASSEE, Fla., Dec. 6, 2023 /PRNewswire/ -- Predatory towing practices in Florida have long been a source of frustration and anger for residents and visitors alike. The state has gained notoriety for towing companies that seem to prey on unsuspecting vehicle owners, often engaging in questionable tactics to maximize their profits. This issue has prompted numerous complaints, legal battles, and calls for reform to protect consumers from the clutches of unscrupulous towing operators. The National Insurance Crime Bureau, the nation's leading not-for-profit organization dedicated to combatting and preventing insurance crime, is helping lead the way to combat these predatory towing practices in the Sunshine State and recently took part in a transportation committee hearing in the Florida House of Representatives focused on this issue.

Key Points: 
  • TALLAHASSEE, Fla., Dec. 6, 2023 /PRNewswire/ -- Predatory towing practices in Florida have long been a source of frustration and anger for residents and visitors alike.
  • The National Insurance Crime Bureau, the nation's leading not-for-profit organization dedicated to combatting and preventing insurance crime, is helping lead the way to combat these predatory towing practices in the Sunshine State and recently took part in a transportation committee hearing in the Florida House of Representatives focused on this issue.
  • Florida law requires property owners to display signs that provide clear information about parking restrictions and the potential for towing.
  • Advocates for consumer rights and fair business practices have called for stricter oversight, increased transparency, and clearer regulations regarding towing practices.

OpusVi Selected by the Arizona Hospital and Healthcare Association (AzHHA) to Supply Nurse Residency Platform to the Arizona Transition to Practice Program

Retrieved on: 
Tuesday, December 5, 2023
Bureau, National Healthcareer Association, Self-assessment, McKinsey & Company, Organization, Bureau of Labor Statistics, Senior, Quality, Nursing, Workforce, HB, RN, AHCCCS, Patient, Preceptor, CommonSpirit Health, Arizona transition zone, Surgical Care Improvement Project, Experiential learning, Providence Health & Services, Premier, Inc., COVID-19, Nursing credentials and certifications, Evidence-based practice, RNS, Teamwork, Curriculum, Partnership, Mentorship, Jewish-American organized crime, Practice, PHOENIX, Safety

OpusVi's nurse residency platform will support the Arizona Transition to Practice program which will serve 480 new graduate nurses and 375 precepting nurses across Arizona as they enter the workforce.

Key Points: 
  • OpusVi's nurse residency platform will support the Arizona Transition to Practice program which will serve 480 new graduate nurses and 375 precepting nurses across Arizona as they enter the workforce.
  • AzHHA and OpusVi are partnering to support a statewide 12-month Arizona Transition to Practice Program to support and develop new nurses, provide evidence-based professional development and address resilience and emergency preparedness.
  • OpusVi's Nurse Residency, Mentorship and Preceptor Program employs best-practice strategies and resources to successfully transition a newly-licensed registered nurse (RN) into a professional role.
  • OpusVi's Nurse Residency Program is delivered via self-directed learning modules, in-person focus groups, experiences on units throughout the healthcare system, interactive exercises and an online community platform.